Viral Infections in Healthy and Immunocompromised Hosts

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Feb 26, 2011

Keywords

ClinConnect Summary

The clinical trial titled "Viral Infections in Healthy and Immunocompromised Hosts" is focused on studying various viral infections, including anogenital herpes, COVID-19, and herpes labialis. Researchers aim to better understand how these viruses affect individuals, especially those with weak immune systems, as they can become more severe or harder to treat in these patients. This study is open to people of all ages who either have a viral infection, are suspected of having one, or have been in close contact with someone who does. This includes healthy individuals as well as those with weakened immune systems.

Participants in the trial can expect to undergo some evaluations, which may include a review of their medical history and tests like blood and saliva samples. Over the first two weeks after joining, they might provide samples up to four times a week, and then possibly twice a week for up to two years. It's important to note that this study does not involve providing any treatments for the infections; instead, it focuses on collecting information to help researchers learn more about these viruses. Additionally, the trial includes provisions for enrolling children and pregnant women, ensuring that their participation is safe and aimed at improving our understanding of viral infections in these groups.

Gender

ALL

Eligibility criteria

• • INCLUSION CRITERIA
• • 1. The protocol is open to people of all ages;
• • 1. Only patients greater than or equal to 2 years of age can be enrolled at the Clinical Center.
• • 2. Patients who are less than 2 years old may be enrolled only remotely and will not be seen at the Clinical Center.
• • 2. a. Persons having (or be suspected of having) a viral infection that is of interest to LID investigators.
• • b. Persons that are a close contact of someone who has (or is suspected of having) a viral infection that is of interest to LID investigators or is about to receive or have recently received a viral vaccine.
• • c. Persons that may have had a recent viral infection that is of interest to LID investigators that has since cleared
• • d. Healthy persons who will serve as controls for (a), (b), or (c) above. These persons will be 18 years of age or older and able to provide informed consent.
• • 3. Adults who are unable to provide initial consent may be enrolled providing procedures per Human Research Protections Program (HRPP) Policy 403 have been followed.
• • 4. Only subjects that are NIH employees or contractors who work at NIH will be enrolled in the COVID19 antibody cohort study on this protocol.
• • EXCLUSION CRITERIA
• • 1. Patients who are unable to safely undergo study procedures and tests.
• • 2. Patients unwilling to have samples collected and stored for future use.
• • 3. For the healthy controls cohort: persons who are \<18 years old, decisionally impaired adults, and pregnant women